查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球流感疫苗市场-2022-2029
市场调查报告书
商品编码
1140687

全球流感疫苗市场-2022-2029

Global Flu Vaccine Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

持续投资使定制流感疫苗生产规模扩大

随着对通用流感疫苗的需求不断增长，创新的科学和资金汇聚在一起，以帮助释放尚未开发的商机。预计流感的迅速传播将超过现有的流感疫苗製造技术，导致流感疫苗接种成本上升，对个人而言，情况相对不利。因此，创新通用流感疫苗需要持续的技术和资金投入。流感疫苗市场的市场参与者正专注于升级流感疫苗的製造工艺，以增加定制疫苗的产量。

流感疫苗是对抗多种病毒株的一种经济有效的方法。预防所有流感的单一疫苗是另一个在流感疫苗市场获得市场关注的开创性概念。此外，製造商正在增加对 mini-HA（血凝素）抗原的关注，其中包含在许多其他病毒中发现的部分流感病毒。通用流感疫苗将减轻每年更新流感疫苗的负担，有助于降低研究人员和製药公司的成本。

地理渗透。

北美将是预测期内的主要地区。

估计北美市场在全球流感疫苗市场占据主导地位。这是由于该地区各国政府加大了努力，包括提高对流感、其影响和流感疫苗接种的认识的卫生计划。此外，高度发达的医疗基础设施和加拿大等国家的优惠报销政策也是预计推动该地区国家市场增长的因素。该地区的多家主要公司已开始对通用流感疫苗进行新的试验。例如，2022 年 6 月，一项针对通用流感疫苗的新试验在 NIH 临床中心开始了第一阶段。本研究探讨了 BPL-1357 的安全性，并证明了粘膜免疫对流感的重要性，以及诱导免疫系统的细胞和抗体臂对不断变化的流感病毒提供更广泛保护的策略。我们正在评估我们是否可以提供

在预测期内，由于对流感疫苗接种的认识不断提高，以及该地区各国政府采取免费流感疫苗接种的举措，预计亚太地区流感疫苗市场将在全球市场中占据很大份额。 .此外，一些新兴国家和发展中国家的流感病例上升预计将支持该地区的市场增长。

竞争格局。

由于主要食品品牌的存在，流感疫苗市场是一个竞争激烈的市场。对全球市场增长做出贡献的重要流感疫苗製造商包括阿斯利康、葛兰素史克、赛诺菲、雅培、Sequirus、田边三菱製药、印度血清研究所、Mylan NV、GDK Biotechnology、华兰生物工程公司、Adimmune Corporation、Sinovac Biotech 、长春生物製品研究所等主要参与者正在根据流感疫苗市场的全球增长战略采用新材料发布或新发布。一些主要的关键参与者正在遵循合併和合作战略来扩展他们的业务。例如，2022 年 5 月，葛兰素史克收购了临床阶段生物製药公司 Affinivax, Inc.。此次收购提供了获得第二阶段开发中的下一代 24 价肺炎球菌候选疫苗和高度创新的 MAPSTM 技术的途径。此次收购还支持强大的创新疫苗和特种药物组合。 2022年7月，葛兰素史克与加拿大政府签署了流感疫苗协议。根据该协议，该公司将供应约 8000 万剂 Arepanrix 和 1600 万剂 Flulaval Tetra。该公司有意从其位于魁北克的 230,000 平方英尺的 Sainte-Foy 工厂采购这两种疫苗。 2020 年 2 月，雅培推出了一种用于广泛预防流感的新疫苗。该疫苗针对儿童和成人的四种流感病毒株针对上一代的三种病毒株提供广谱保护。该疫苗仅批准用于 3 岁以下儿童。对4种流感病毒株有效。

COVID-19 的影响将对全球流感疫苗市场产生积极影响。

由于 COVID-19 疫苗在大流行的早期阶段尚未上市，因此人们越来越有兴趣评估流感疫苗在 COVID-19 易感性和严重性中的作用。与未接种流感疫苗的人相比，接种流感疫苗的人 COVID-19 检测呈阳性的可能性降低了 24%。结论：接种流感疫苗的患者不太可能需要住院或机械通气并且住院时间较短。流感疫苗可减轻 COVID-19 的负担。一些製造商在大流行期间增加了销量。例如，2020 年 10 月，赛诺菲第三季度受到创纪录的流感疫苗销售增长和 Dupixent 成功的推动。仅流感疫苗销售额就增长了 44.9%，达到创纪录的 10.7 亿欧元，成功部分抵消了 COVID-19 爆发对脑膜炎疫苗 Menactra 及其成人加强疫苗和旅行疫苗的影响。

本报告提供了大约 61 个市场数据表、57 个图表和 170 页有关全球流感疫苗市场的信息。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按类型划分的市场细分
  • 按分销渠道划分的市场细分
  • 按应用划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 继续投资扩大定制流感疫苗的生产规模
      • 对通用流感疫苗的需求增加
    • 限制因素
      • 产品的高成本和疫苗的剂量限制了其吸收
    • 商机
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 供应链分析
  • 价值链分析
  • PEST 分析
  • 定价分析
  • 监管分析
  • 保险报销分析
  • 未满足的需求
  • 专利趋势

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按类型

  • 全病毒疫苗
  • 分裂病毒疫苗
  • 亚单位疫苗
  • 减毒活疫苗

第 8 章分销渠道

  • 机构投资者
  • 医院
  • 区域诊所
  • 公共卫生机构
  • 工作场所
  • 零售
  • 零售药房
  • 邮购药房

第 9 章按应用程序

  • 适用于 3 岁以下儿童
  • 适用于 3 岁以上的儿童和成人

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第 12 章公司简介

  • 阿斯利康
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • GlaxoSmithKline PLC
  • Sanofi
  • Abbott Laboratories
  • Seqirus
  • Mitsubishi Tanabe Pharma
  • Serum Institute of India Pvt. Ltd
  • Mylan NV
  • GDK Biotechnology
  • Hualan Biological Engineering Inc.
  • Adimmune Corporation
  • Sinovac Biotech
  • Changchun Institute of Biological Products（List Not Exhaustive）

第13章 重要考察

第14章 DataM

简介目录
Product Code: DMHCIT3078

Market Overview

Flu Vaccine Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 8.8% during the forecast period (2022-2029).

The flu vaccine is inactivated, indicating that it includes the killed influenza virus, or a recombinant vaccine, implying that it was made without exploiting virus particles. Flue vaccination is safe and effective. Healthcare providers infuse the vaccine into muscles or skin, encouraging the immune system to produce antibodies to the influenza virus. Medical professionals administer the "flu shot" vaccine as a single dose of liquid injected through the skin into the muscle. The health care professionals inject the flu vaccine into the deltoid muscle at the side of the arm, using alcohol rubbed over the skin for sterilization. Market players in the flu vaccines are increasing their R&D activities to develop innovative vaccines that can treat COVID-19. They are helping persons to refrain from visiting doctors amidst ongoing pandemics. Increased flu vaccine availability is expected to reduce the stress on healthcare systems and minimize exposure to COVID-19.

Market Dynamics: Sustained investments help to scale-up production of tailor-made flu vaccines

The demand for universal flu vaccines increases innovative science and financing to join forces to support exploit of untapped opportunities. The rapid arrival of influenza is expected to overtake the prevailing flu vaccine production technologies, resulting in increased costs of flu shots, which is comparatively ominous for individuals. Thus, there is a need for continuous investments in both technical and financial to innovate universal flu vaccines. The flu vaccines market's market players are focusing on upgrading the flu vaccine manufacturing processes to raise the production of tailor-made vaccines.

Flu vaccine is a Cost-efficient way to combat multiple viral strains. The single vaccine that safeguards against all flu is another groundbreaking concept gaining market players' traction in the flu vaccines market. Moreover, the manufacturers are increasing their focus on mini-HA (Hemagglutinin) antigens that include parts of the flu virus found in numerous other viruses. Universal flu vaccines assist in reducing the burden of yearly updates in flu shots, therefore, saving on costs for researchers and pharma companies.

Market Segmentation: The whole virus segment accounted for the highest share in global flu vaccine market.

The flu vaccine market has been classified into whole virus vaccines, split virus vaccines, subunit vaccines, and live attenuated virus vaccines based on the vaccine.

The whole virus vaccines segment held a dominant position with a major share in terms of value in the global market and is projected to remain at its position over the forecast period. Whereas the live attenuated virus vaccines segment is projected to record a considerable growth rate in the global market during the forecast period, owing to the increasing adoption of advanced vaccines for prevention purposes.

The flu vaccine market has been classified into anti-intrusion bars, heat exchangers, sound insulation, and others based on the application.

Adults and Children over 3 year's segment dominated the global flu vaccine market in the forecast period. The adults and children aged 3 years and above segment are estimated to contribute the maximum share in terms of value in the target market due to increasing incidences of flu viruses among adults and children over 3 years of age globally.

Geographical Penetration: North America is the dominating region during the forecast period.

The North America market is estimated to hold the dominant position in the global flu vaccines market. This is due to the governments increasing initiatives, such as health programs for expanding awareness concerning influenza, its possible effects, and flu vaccination in countries in the region. Highly developed healthcare infrastructure and the existence of favorable reimbursement policies in countries such as Canada are additional factors projected to boost market growth in countries in the region. Various key players in the region started new trials for the universal flu vaccine. For instance, in June 2022, a new trial for the universal flu vaccine started at NIH Clinical Center in phase 1. This study examines the safety of BPL-1357 and assesses the importance of mucosal immunity against flu and whether a strategy of inducing both the cellular and antibody arms of the immune system can provide broader protection against the ever-changing influenza virus

The Asia Pacific flu vaccine market is projected to gain a significant share in the global market over the forecast period due to increasing awareness regarding flu vaccination and government initiatives for free flu vaccinations in countries in the region. Moreover, the increasing patient pool for flu in several developing and poorly developed countries is expected to support the growth of the market in the region.

Competitive Landscape:

The flu vaccine market is highly competitive, owing to the presence of big food brands. The critical flu vaccine players which are contributing to the growth of the global market include AstraZeneca, GlaxoSmithKline PLC, Sanofi, Abbott Laboratories, Seqirus, Mitsubishi Tanabe Pharma, Serum Institute of India Pvt. Ltd, Mylan NV, GDK Biotechnology, Hualan Biological Engineering Inc., Adimmune Corporation, Sinovac Biotech, and Changchun Institute of Biological Products, among others. The major players are adopting new launches based on new material launches and expansion strategies for global growth in the flu vaccine market. Some major key players follow merger and collaboration strategies to expand their business. For instance, in May 2022, GSK acquired clinical-stage biopharmaceutical company Affinivax, Inc. This acquisition provides access to next-generation 24-valent pneumococcal vaccine candidates in phase II development and highly innovative MAPSTM technology. This acquisition also supports a strong portfolio of innovative vaccines and specialty medicines. In July 2022, GSK entered into an agreement with the Government of Canada for the influenza vaccine. The company supplies nearly 80 million doses of Arepanrix and 16 million doses of Flulaval Tetra under the deal. The company intends both vaccines from its 230,000ft² Sainte-Foy facilities in Quebec. In February 2020, Abbot launched a new vaccine for wide protection against influenza. This vaccine offered wide coverage protection against four flu virus strains for children and adults versus three strains in the previous generation. This vaccine is approved for only children below the age of 3 years. It is effective against four different flu virus strains.

COVID-19 Impact: Positive impact on the global flu vaccine market.

COVID-19 vaccine is not available in the market at the initial stage of the pandemic, so there is interest in assessing the role of the influenza vaccine in COVID-19 susceptibility and severity. The possibility of testing positive for COVID-19 was reduced in patients who received an influenza vaccine compared to those who did not by 24%. Patients vaccinated with the flu vaccine were less likely to require hospitalization or mechanical ventilation and had a shorter hospital length of stay. The flu vaccine reduces the burden of COVID-19. Some manufacturers increase their sales during the pandemic. For instance, in October 2020, Sanofi's Q3 was boosted by record growth in flu vaccine sales and Dupixent success. Sales for influenza vaccines alone grew by a record 44.9% to €1.07 billion during the quarter, which managed to partially offset the impact of the COVID-19 outbreak on the meningitis vaccine Menactra and its adult booster and travel vaccines.

The global flu vaccine market report would provide an access to approximately 61 market data tables, 57 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Distribution Channel
  • 3.3. Market Snippet by Application
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Sustained investments help to scale up production of tailor-made flu vaccines
      • 4.1.1.2. Increasing demand for universal flu vaccines
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of the product coupled with the dosage of the vaccine to limit adoption
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
  • 7.3. Market Attractiveness Index, By Type Segment
    • 7.3.1. Whole virus vaccines*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Split vurus vaccines
    • 7.3.3. Subunit vaccines
    • 7.3.4. Live attenuated virus vaccines

8. By Distribution Channel

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 8.3. Market Attractiveness Index, By Distribution Channel Segment
    • 8.3.1. Institutional*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Hospitals
    • 8.3.3. Community clinics
    • 8.3.4. Public health agencies
    • 8.3.5. Workplaces
    • 8.3.6. Retails
    • 8.3.7. Retail pharmacy
    • 8.3.8. Mail order pharmacy

9. By Application

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 9.3. Market Attractiveness Index, By Application Segment
    • 9.3.1. For Children below 3 years*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. For Adults and Children over 3 years

10. By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. AstraZeneca*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. GlaxoSmithKline PLC
  • 12.3. Sanofi
  • 12.4. Abbott Laboratories
  • 12.5. Seqirus
  • 12.6. Mitsubishi Tanabe Pharma
  • 12.7. Serum Institute of India Pvt. Ltd
  • 12.8. Mylan NV
  • 12.9. GDK Biotechnology
  • 12.10. Hualan Biological Engineering Inc.
  • 12.11. Adimmune Corporation
  • 12.12. Sinovac Biotech
  • 12.13. Changchun Institute of Biological Products (List Not Exhaustive)

13. Premium Insights

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us